There are several forms of acute lymphoblastic leukemia (ALL), with B-cell ALL being the most common (around 75% of cases). A range of treatments are available for ALL, including chemotherapy, radiation therapy, and stem cell transplantation. Chimeric antigen receptor T-cell (CAR-T) therapy is a novel cellular therapy that has demonstrated potential for treating other hematological malignancies, such as B-cell non-Hodgkin lymphoma and multiple myeloma.

In this podcast, Reuben Benjamin, MBBS, FRCPath, PhD, from Kings College Hospital in London, London, UK, Cameron Turtle, MBBS, PhD, FRACP, FRCPA, from the Fred Hutchinson Cancer Research Center, Seattle, WA, Claire Roddie, MD, PhD, from University College London, London, UK, Nirali Shah, MD, from the National Cancer Institute, Bethesda, MD, and Bianca Santomasso, MD, PhD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discuss the latest updates and future directions for the use of CAR-T therapy in the treatment of ALL.

The post Key updates on CAR-T therapy for ALL appeared first on VJHemOnc.